First Study of Neoadjuvant Use of PARP Inhibitor Shows Promise for Early-Stage, BRCA+ Breast Cancer Patients

Excerpt:

In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib once daily prior to surgery had no evidence of disease at the time of surgery. If further validated in larger, confirmatory trials, the oral medication could replace chemotherapy for these patients.

“The trial, which expands upon a feasibility study published in npj Breast Cancer, was presented today as an oral presentation at the 2018 American Society of Clinical Oncology Annual Meeting by Jennifer Litton, M.D., associate professor of Breast Medical Oncology.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Many Women With Breast Cancer May Not Need Chemo, but Beware Misleading Headlines

Excerpt:

Findings from a major international clinical trial suggest a significant number of women with the most common form of early-stage breast cancer do not need chemotherapy after surgery.

“The results of the so-called TAILORx trial were presented yesterday at the annual meeting of the American Society of Clinical Oncology and concurrently published in the New England Journal of Medicine.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Circulating Tumor Cells and Benefit of Adjuvant Radiotherapy in Early Breast Cancer

Excerpt:

“In a study reported in JAMA Oncology, Goodman et al found that adjuvant radiotherapy was associated with better outcome in patients with early breast cancer who had detectable circulating tumor cells (CTCs).

“The analysis included data from patients with stage pT1 to pT2 and pN0 to pN1 breast cancer and known CTC status from the National Cancer Database (NCDB) from January 2004 to December 2014 and the phase III SUCCESS trial from September 2005 to September 2013.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast Cancer

Excerpt:

“Myriad Genetics, Inc. (MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.  A key finding is that Myriad’s EndoPredict® (EPClin) significantly outperformed Oncotype DX® Recurrence Score at predicting the risk of disease recurrence in patients with early-stage breast cancer.

“In the article, Sestak et al. compared the prognostic value that four different commercial tests add to the Clinical Treatment Score (nodal status, tumor size, grate, age, endocrine treatment) for predicting distant recurrence (0-10 years) and late-distant recurrence (5-10 years) of breast cancer.  The analysis included data from 774 postmenopausal women with ER+/HER2- breast cancer with node-negative disease or up to three positive lymph nodes, which is the most common form of breast cancer.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


FDA Approves Stereotactic Radiotherapy System for Breast Cancer

Excerpt:

“The FDA has approved a novel breast-specific stereotactic body radiotherapy (SBRT) device known as GammaPod as a treatment for patients with early breast cancer, based on findings from a 17-patient study.

“In the small clinical trial, GammaPod was effectively used to deliver a single ‘boost’ radiation dose of 8 Gy directly to the tumor, while only eliciting grade 1 adverse events (AEs). The system uses a vacuum-assisted breast cup guided by a CT simulator with 1 mm slice thickness to immobilize the breast, which ensures the accurate delivery of radiation to the tumor.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Acupuncture Reduced AI-Related Joint Pain in Early-Stage Breast Cancer

Excerpt:

“Undergoing acupuncture significantly reduced joint pain related to treatment with aromatase inhibitors (AIs) in postmenopausal women with early-stage breast cancer compared with both sham acupuncture and no treatment at all, according to data from the Southwest Oncology Group (SWOG) S1200 trial presented at the 2017 San Antonio Breast Cancer Symposium, held December 5–9.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


ESMO 2017 Press Release: Study in Early Stage Breast Cancer Shows That Even Small Tumours Can Be Aggressive

Excerpt:

“Even small tumours can be aggressive, according to a study in patients with early stage breast cancer that will be presented at the ESMO 2017 Congress in Madrid. Researchers found that nearly one in four small tumours were aggressive and patients benefited from chemotherapy. Aggressive tumours could be identified by a 70-gene signature.

” ‘Our results challenge the assumption that all small tumours are less serious and do not need adjuvant chemotherapy,’ said lead author Dr Konstantinos Tryfonidis, a researcher at the European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


How Decision-Making Habits Influence the Breast Cancer Treatments Women Consider

Excerpt:

“A new study finds that more than half of women with early stage breast cancer considered an aggressive type of surgery to remove both breasts. The way women generally approach big decisions, combined with their values, impacts what breast cancer treatment they consider, the study also found.

“Contralateral prophylactic  – a procedure to remove both breasts when  occurs in only one breast – has become increasingly popular in recent years, with more than 20 percent of  opting for it. For most women, removing the unaffected breast does not improve survival.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Targeted Radiotherapy Limits Side Effects of Breast Cancer Treatment

Excerpt:

“Breast cancer patients who have radiotherapy targeted at the original tumour site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, and their cancer is just as unlikely to return, according to trial results published* in The Lancet (link is external) today (Wednesday).

“The Cancer Research UK-funded IMPORT LOW trial** revealed that five years after treatment, almost all patients were disease free.***

“The researchers at 30 radiotherapy centres across the UK, led by The Institute of Cancer Research, London(link is external), and the Cancer Research UK Cambridge Centre(link is external), studied more than 2,000 women aged 50 or over who had early stage breast cancer that was at a low risk of coming back.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.